Reata Pharmaceuticals Inc (NASDAQ:RETA) saw an upside of 0.09% to close Friday at $172.32 after adding $0.15 on the day. The 5-day average trading volume is 822,980 shares of the company’s common stock. It has gained $172.36 in the past week and touched a new high 4 times within the past 5 days. An average of 729,300 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,034,628.
RETA’s 1-month performance is 1.87% or $3.07 on its low of $168.56 reached on 08/24/23. The company’s shares have touched a 52-week low of $21.83 and high of $172.36, with the stock’s rally to the 52-week high happening on 09/21/23. YTD, RETA has achieved 353.59% or $134.33 and has reached a new high 43 times. However, the current price is down -0.02% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
RETA stock investors last saw insider trading activity on Sep 14.Loewen Andrea (SVP, Global Regulatory Affairs) most recently sold 3,175 shares at $172.03 per share on Sep 14. This transaction cost the insider $546,181. SVP, Chief Accounting Officer, Anand Bhaskar, sold 406 shares at a price of $169.20 on Sep 05. Then, on Aug 16, COO, CFO and President Soni Manmeet Singh sold 1,755 shares at a price of $168.41 per share. This transaction amounted to $295,566.
Valuation Metrics
RETA stock has a beta of 1.41. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 279.62 while the price-to-book (PB) in the most recent quarter is 74.71.
Reata Pharmaceuticals Inc’s quick ratio for the period ended June 29 was 3.19, with the current ratio over the same period at 3.21. As well, the company’s long term debt to equity for the quarter ending June 29 was 3.32, while the total debt to equity was 3.42. In terms of profitability, the gross margin trailing 12 months is 91.58%. The trailing 12-month EBITDA margin is -12495.67% while for the period ending June 29, Reata Pharmaceuticals Inc’s operating margin was -1455.08%. The firm’s gross profit as reported stood at $280.25 million against revenue of $2.22 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 138.11% to $193.0 million, while revenue of -$116.12 million was 160.17% off the previous quarter. Analysts expected RETA to announce -$2.88 per share in earnings in its latest quarter, but it posted $4.65, representing a 261.50% surprise. EBITDA for the quarter stood at more than -$94.54 million. RETA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 415.3 million, with total debt at $166.0 million. Shareholders hold equity totaling $38.15 million.
Let’s look briefly at Reata Pharmaceuticals Inc (RETA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 87.45% to suggest the stock is trending Overbought, with historical volatility in this time period at 2.86%.
The stock’s 5-day moving average is $172.17, reflecting a +0.19% or $0.32 change from its current price. RETA is currently trading +2.12% above its 20-day SMA, +72.68% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +59.99% and SMA200 by+334.93%.
Stochastic %K and %D was 97.92% and 98.16% and the average true range (ATR) pointed at 0.56. The RSI (14) points at 84.61%, while the 14-day stochastic is at 98.92% with the period’s ATR at 0.99. The stock’s 9-day MACD Oscillator is pointing at 0.13 and 0.82 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Reata Pharmaceuticals Inc (NASDAQ: RETA), TD Cowen launched coverage with an Outperform rating. Analysts offering their rating for RETA stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate RETA as a “sell,”, while 10 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is RETA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $172.00 and a high of $173.00, with their median price target at $172.50. Looking at these predictions, the average price target given by analysts is for Reata Pharmaceuticals Inc (RETA) stock is $172.45.
